Introduction
Administration of antenatal corticosteroids (ACS) to women at risk for preterm delivery is one of the most effective life-saving treatments in perinatal medicine. ACS has been shown to significantly reduce the risk of respiratory distress syndrome, intraventricular haemorrhage (IVH), necrotising enterocolitis (NEC), early sepsis and neonatal death in preterm infants. 1, 2 Treatment with ACS is therefore recommended to all women at risk for preterm birth prior to 34 weeks of gestation. [3] [4] [5] There are limited data on ACS for extremely preterm birth. A meta-analysis showed no reductions of neonatal mortality and morbidity prior to 26 weeks gestation, 6 whereas more recent studies have indicated similar 7, 8 or even more pronounced benefits 9 from ACS for extremely preterm births. Whether the timing of ACS is of importance for outcome among extremely preterm infants has also been sparsely investigated. 10, 11 In a recent large retrospective cohort study from the Canadian neonatal network, higher odds for severe neonatal morbidity or mortality were seen in preterm infants born at 24-33 weeks of gestation with an administration-to-birth interval of ACS shorter or longer than 1-7 days and, if anything, these findings were more pronounced in infants <29 weeks of gestation. 9 Given that pregnant women delivering high-risk infants at extremely short gestations may deliver before ACS have been administered, or deliver at various time intervals after ACS, a better understanding of the effects and importance of the administration-to-birth interval of ACS for outcome in extremely preterm infants is needed. The objective of this prospective population-based cohort study was to investigate the impact of the administration-to-birth interval of ACS on survival of extremely preterm infants.
Methods
The Extremely Preterm Infants in Sweden Study (EXPRESS) included all pregnant women residing in Sweden and delivering extremely preterm infants, born at 22-26 completed weeks of gestation, from 1 April 2004 to 31 March 2007. The cohort studied herein consisted of all live-born infants (n = 707), including multiple births and infants with malformations, whereas stillborn infants (n = 304) and infants born outside Sweden and transferred after birth to Sweden for neonatal care were excluded. Detailed characteristics of EXPRESS have been reported elsewhere. [12] [13] [14] Among liveborn infants, 520 survived the neonatal period and 497 were alive at 1 year old ( Figure S1 ).
The procedures for data collection and other methodological details have been previously described. 13 In brief, during the study period, Sweden had seven healthcare regions, each served by a regional level III hospital. The general policy was to centralise extremely preterm deliveries to these regional hospitals. Data on mothers were collected at the time of delivery. Data on live-born infants were collected prospectively during the first 180 days of hospitalisation or until discharge or death. Information on infant deaths after discharge home until 1 year was obtained from the National Population Registry.
Maternal hypertensive disease was defined as essential hypertension, preeclampsia or eclampsia. Information on maternal smoking was obtained at the first antenatal visit, and the information was dichotomised (smoking/nonsmoking). Preterm prelabour rupture of membranes (PPROM) was defined as spontaneous rupture of the membranes at least 1 h before the onset of contractions.
Live birth and perinatal mortality were defined according with WHO. 15 Gestational age was recorded in completed weeks and based on ultrasound in 95% of pregnancies. Birth weight was evaluated in accordance with the national standard for normal fetal growth 16 and expressed in standard deviation (SD) scores. Infants with birth weight more than 2 SD below the mean were classified as small for gestational age (SGA). IVH was graded in accordance with data from Papile et al., 17 and periventricular leukomalacia (PVL) was defined as proposed by de Vries et al. 18 Retinopathy of prematurity (ROP) was defined in accordance with the International Classification for Retinopathy of Prematurity 19 and NEC according to Bell et al., where stage two or more were considered as diagnostic. 20 Severe bronchopulmonary dysplasia (BPD) was defined as the need for ≥ 30% oxygen at a postmenstrual age of 36 weeks. 21 A complete course with ACS to the pregnant mothers consisted of two doses of 12 mg betamethasone 24 h apart. In the EXPRESS-database, time from the first ACS dose to delivery in hours had been prospectively collected. We categorised all live-born infants into four categories according to the time interval from the first ACS dose to delivery: <24 h; 24-47 h; 48 h to 7 days; and >7 days. The EXPRESS-database also provided information whether an incomplete (one dose) or complete course (two doses) had been administered. The category <24 h comprised infants that had received either an incomplete (one dose) or a complete course (two doses) most likely reflecting that the study was descriptive with no attempts in the study framework to standardise treatment or compliance to treatment protocols. Additional categories consisted of infants unexposed to ACS and those exposed to ACS but with unknown timing.
Outcomes were neonatal (0-28 days) and infant survival (0-365 days). Infant survival without major neonatal morbidity, i.e. survival without IVH grade ≥ 3, ROP stage ≥ 3, PVL, NEC or severe BPD, was also included as an outcome.
The study was approved by the Regional Research Ethics Board, Lund University, Lund, Sweden (date of approval 1 July 2004; reference number 42/2004). The parents provided oral informed consent for data acquisition.
Statistical analyses
Data are presented as numbers and proportions (percentages) if not stated otherwise. The differences across ACS administration-to-birth interval categories were presented using descriptive statistics. Cox proportional hazards regression analysis was used to estimate hazard ratios (HR) for survival across the ACS administration-to-birth interval categories, including one unexposed category and one dummy category representing unknown ACS timing. Based on available knowledge on optimal timing for ACS administration, the category 48 h to 7 days was considered as reference category, i.e. HR = 1.00. HRs for neonatal and infant survival in relation to ACS administration-to-birth intervals were evaluated in a multiple Cox proportional hazards regression model adjusting for factors known to affect infant mortality: maternal smoking; 22 and surfactant therapy within 2 h after birth. The rationale for including surfactant therapy within 2 h after birth in the model was that this intervention has been shown to be associated with significantly reduced infant mortality in randomised controlled trials and in the EXPRESS-study, independently of ACS exposure. 13, 25 Nonetheless, because early surfactant therapy may be in the causal pathway, we ran a sensitivity analysis without surfactant in the model for infant mortality. Cumulative neonatal and infant survival adjusted for covariates was also determined using Kaplan-Meier survival analyses. The odds for surviving without major neonatal morbidity were analysed using a multiple logistic regression model adjusting for the same factors as for the analysis in the Cox proportional hazards regression. Results are presented as odds compared with the reference category of ACS 48 h to 7 days before birth, odds ratio (OR) = 1.00. We made no adjustments for multiple births as our analyses are to be interpreted as exploratory. All tests were two-sided, and a P-value of less than 0.05 was considered as statistically significant.
Statistical calculations were performed using JMP 11.0 (SAS Institute, Cary, NC, USA) and the IBM SPSS Statistics V22 or higher (IBM Corporation).
Results
Among 707 infants born alive at 22-26 weeks of gestation, 591 (84%) had been exposed to ACS, whereas 85 (12%) were unexposed to ACS, and in 31 infants (4%) data regarding ACS exposure were missing. Of the infants exposed to ACS, 149 (25%) were born less than 24 h after the first ACS dose, 66 (11%) were born within 24-47 h, 171 (29%) were born within 48 h to 7 days, and 103 (17%) infants were born more than 7 days after the first ACS dose. One-hundred and two (17%) infants have been exposed to ACS without any information on the administration-to-birth time interval.
Maternal characteristics
Maternal smoking in pregnancy did not differ significantly between ACS exposure categories. Pregnant women with hypertensive disease had more often received ACS treatment than women without such disease (Table 1) . ACS, antenatal corticosteroids; PPROM, preterm prelabour rupture of membranes; SGA, small for gestational age (birthweight more than 2 SD below the mean of a national fetal weight-based growth standard). Data are numbers (percentages). *Essential hypertension and/or preeclampsia and/or eclampsia.
Obstetric characteristics
Among unexposed and those exposed to ACS <24 h before delivery, the proportion of women delivered at level III hospitals was lower than in all other ACS administrationto-birth intervals. PPROM was less frequent in women delivering <24 h after ACS administration compared with all other ACS administration-to-birth intervals. Tocolytic treatment was less frequent in pregnant women unexposed to ACS than in women treated with ACS, irrespective of administration-to-birth interval. The proportions of placenta previa and placenta abruption did not vary in relation to administration-to-birth interval of ACS (Table 1) .
Infant characteristics
Infants unexposed to ACS were more likely to be born at a lower gestational age than infants exposed to ACS, were less likely to be SGA and less likely to be treated with surfactant within 2 h after birth. In the exposed groups, there was an association between ACS administration-to-birth interval and gestational age: the longer time interval, the higher gestational age. Accordingly, proportions of infants born at 22-23 gestational weeks ranged from 26% in the administration-to-birth interval <24 h to 4% in the ACS-category >7 days. In infants born at 26 weeks of gestation, the corresponding proportions ranged from 26% in the administration-tobirth interval <24 h to 44% in the time interval >7 days.
There were no significant differences between ACS categories regarding distributions of infant gender (P = 0.23) or multiple births (P = 0.18; Table 1 ).
Neonatal and infant survival in relation to ACS and administration-to-birth intervals
Of the 707 live-born infants, 520 (74%) were alive at 28 days and 497 (70%) were alive at 1 year old. Neonatal survival was 39% in the unexposed group, and ranged from 71 to 85% in infants exposed to ACS at different administration-to-birth intervals. Infant survival was 35% in the unexposed group and ranged from 71-80% in the exposed groups (Table 2 ).
In the fully adjusted model, the lowest HRs for neonatal and infant survival were found among infants unexposed to ACS [HR = 0.26; 95% confidence interval (CI) = 0.15-0.43]. Extremely preterm infants born <24 h after ACS as well as those born more than 7 days after ACS administration also had lower HRs for survival (HR = 0.53; 95% CI = 0.33-0.87 and HR = 0.56; 95% CI = 0.32-0.97, respectively) than infants born 48 h to 7 days after ACS administration. Survival in infants born at 24-47 h did not differ from that in infants born 48 h to 7 days after ACS administration ( Figure 1 ; Table 3 ).
The sensitivity analysis, excluding surfactant within 2 h after birth, did not alter the interpretation in a significant way: the estimated HR for infant survival in infants unexposed to ACS was 0.29 (versus 0.26 with surfactant in the model); it was 0.72 (versus 0.53 with surfactant in the model) for infants exposed to ACS <24 h before birth; 1.16 (versus 1.60) for those receiving ACS 24-48 h before birth; 0.63 (versus 0.56) for infants who received ACS >7 days before birth; and 0.64 (versus 0.53) in the category with unknown timing of ACS [in both models, the reference category (HR = 1) was ACS 48 h to 7 days before birth].
Infant survival with no major morbidity in relation to ACS and administration-to-birth intervals
Of the 707 live-born infants, 226 (32%) survived to 1 year old and without any major neonatal morbidity. Survival without major neonatal morbidity among live-born infants was 14% in unexposed infants and 30-39% in steroidexposed infants, indicating that any ACS exposure was valuable (Table 2 ). There was no statistically significant (Table 3 ). In the fully adjusted model, the OR for infant survival without major neonatal morbidity was significantly lower in infants unexposed to ACS (OR = 0.33; 95% CI = 0.16-0.69; Table 3 ).
Discussion

Main findings
We found clear associations between timing of ACS and survival in extremely preterm infants. Shorter or longer administration-to-birth intervals than 24 h to 7 days were associated with a doubled risk for infant mortality. The lowest survival was found in infants unexposed for ACStheir adjusted infant mortality risk was five times higher than in infants in the reference group exposed to ACS 48 h to 7 days before birth. Similar results were found for neonatal survival and infant survival without major neonatal morbidity.
Strengths and limitations
The strengths of this study include prospective enrollment of all extremely preterm births -including delivery room deaths -in Sweden over a 3-year period. The study is one ACS, antenatal corticosteroids; CI, confidence interval; HR, hazard ratio; OR, odds ratio. *Adjusted for maternal smoking, maternal blood pressure disease, placenta previa, placental abruption, PPROM, regionalisation of care, gestational age, SGA, infant gender and surfactant therapy within 2 h after birth. **Survival without any of the following: IVH ≥ 3, ROP ≥ 3, severe BPD, PVL or NEC.
of the largest 7, 9 and the only population-based cohort evaluated for effects of ACS, and of timing of ACS, in all liveborn infants born at 22-26 weeks of gestation. The ACS administration-to-birth interval was prospectively collected in hours. The outcomes were robust and clinically highly relevant. The sample size allowed for adjusted analyses of survival in relation to timing of ACS-administration and several potential confounders. The case-mix of our cohort 12, 13 is similar to what has been reported in other contemporary cohorts of extremely preterm infants.
We excluded stillborn infants. Among stillborn infants alive at onset of labour (n = 66/304; 22% of all stillborns), a minority (n = 22/66; 30% of stillborns alive at onset of labour) had been treated with ACS, meaning that these fetuses had been proactively managed. Excluding intrapartum mortality may therefore have introduced some bias, overestimating the protective effects of ACS at the time it was administered. However, under the premise that the infant was live-born, our risk estimates of no or untimely ACS are valid.
During the study period, a restricted treatment policy was -if parents agreed -used in some but not all of the participating hospitals in Sweden for births that were considered nonviable. The EXPRESS-database does not contain specific information on reasons for not treating with ACS; however, a recommendation to withhold treatment rested mainly on regional guidelines focusing on management of extremely short gestations or severe malformations. Among infants born at 22 weeks of gestation, 29/49 (59%) did not receive ACS, at 23 weeks of gestation the corresponding proportion was 14/99 (14%), and in infants born at 24 weeks of gestation the proportion not receiving ACS was 7/137 (5.1%). Accordingly, crude estimates of survival in relation to ACS exposure and administration-to-birth intervals are likely to be confounded by indication. To resolve this issue, we only present mortality data adjusted for gestational age.
Small numbers of 22-week fetuses, with only 20 exposed to ACS and five survivors, make generalisability of our findings to this group limited. And although based on 707 live-born infants, limitations in numbers may also contribute to wide confidence intervals for some of our risk estimates.
We cannot exclude that other confounding factors than those included herein were unevenly distributed between categories and affected our results. We excluded tocolysis from our multivariate analyses because, in univariate testing, survival was not related to this variable, and because of some missing data (n = 29) on use of tocolysis. Other and unknown differences in case-mix between the different ACS categories may have occurred. Moreover, our results cannot be extrapolated to other drugs or dosing regimens than the ones used in Sweden. Finally, we had no data on fetal-infant survival among pregnant women exposed to ACS before 27 weeks of gestation but who, for various reasons, did not deliver before this upper limit for inclusion.
Interpretation
Antenatal corticosteroid treatment has previously been associated with reduced mortality in extremely preterm infants born after 22-26 weeks of gestation. 7, 8, 26 The magnitude of an effect of ACS in those studies varied between an adjusted HR of 0.38 and 0.72, which is similar to our findings. In contrast, a meta-analysis concluded that there were no effects from ACS on neonatal mortality and morbidity in extremely preterm infants. 6 Adding the data provided in our study is likely to change that conclusion.
Animal studies have shown the greatest benefits from ACS on surfactant production when delivery occurs between 24 h and 7 days after a complete course of ACS. 27, 28 However, human studies are more contradictory. Some studies have found a decline in the effectiveness of ACS over time, 9, 10, 29, 30 whereas others failed to do so. 11, [31] [32] [33] The conflicting results may be attributed partly to the use of diverse outcome measures. Our results are in line with a recent study where the authors found that ACS for preterm birth at 24-34 weeks of gestational age had maximum beneficial impact on neonatal morbidity and mortality when administered 1-7 days before birth. In that study, the decline in effectiveness of ACS after 7 days was primarily observed among neonates born at 24-28 weeks of gestation. 9 We found decreased survival with an ACS administration-to-birth interval exceeding 7 days. The NIH Consensus Development Panel in 2000 recommended that a repeat course of corticosteroids should be reserved for women participating in controlled trials. 34 This recommendation was subsequently endorsed by the Canadian Society of Obstetricians and Gynecologists in 2003. Since then, large randomised controlled trials have reported conflicting results. 35, 36 The latest Cochrane review concluded that repeat courses of corticosteroids were associated with a reduction in the incidence and severity of neonatal lung disease and a small reduction in size at birth. 37 Recent work indicate no harm at follow-up to school age in those exposed to repeat courses of ACS at 24-28 weeks and born later after on average 32 weeks of gestation. 38 Observational data from adolescence and young adult age also suggest long-term safety after exposure to repeat ACS. 39 Repeat or rescue doses of glucocorticoids may therefore be considered in women at continued risk of preterm birth 7 or more days after an initial course. 37 The included infants were born almost a decade ago. Since then neonatal care has improved and the evidence for less invasive ventilation strategies has become clearer. 40 Still, we think our findings are generalisable for the current extreme preterm population as in 2013-2014, the proportions of infants born at 22-26 weeks of gestation in Sweden who were intubated at birth and mechanically ventilated were similar to those in EXPRESS 12 (unpublished data from the Swedish Neonatal Quality registry).
Conclusion
In summary, this study suggests an optimal administrationto-birth interval for ACS in extremely preterm infants of 1-7 days, but also that all ACS is valuable. This knowledge is important for clinicians when managing extremely preterm births and trying to administer ACS within the most beneficial window of time.
Given that pregnant women continue to deliver extremely preterm at various ACS time intervals, future areas for research include exploration of short (neonatal morbidity) and longer term (developmental, neurocognitive) outcomes in relation to administration-to-birth intervals. The optimal dosing (one or two doses, dose in mg) and dosing intervals (6, 12 or 24 h apart) should preferably also be tested.
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